All In Biotech

Drug Trial Radar · NCT05267626

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

159

Planned (sponsor's estimate)

Start

Apr 4, 2022

Primary completion

Feb 28, 2027

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Aulos Bioscience, Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.

Conditions

  • Advanced Solid Tumor
  • Metastatic Cancer
  • Cutaneous Melanoma
  • Non-Small Cell Lung Cancer

Interventions

  • AU-007Drug

    Monoclonal Antibody Targeting IL-2

  • AldesleukinDrug

    IL-2

  • AvelumabDrug

    Monoclonal Antibody Targeting PD-L1

  • NivolumabDrug

    Monoclonal Antibody Targeting PD-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of AU-007Time frame: Day 1 thru end of treatment (EOT) visit (28 days after last dose)
  2. Establish the maximum tolerated dose (MTD) and/or RP2DTime frame: Day 1 thru EOT visit (28 days after last dose)

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Minnesota Oncology and Hematology PA

    Minneapolis, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Carolina Biooncology Institute

    Huntersville, North Carolina · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Texas Oncology (Balcones) - SCRI

    Austin, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START South Texas Accelerated Research Therapeutics

    San Antonio, Texas · Recruiting

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Southside Cancer Care Centre

    Miranda, New South Wales, Australia · Recruiting

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Sunshine Hospital

    Saint Albans, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.